⚠️ Critical Safety Warning
Dosage is critical for safety. Always start with lower doses, especially if you're inexperienced or uncertain. Individual sensitivity varies significantly. These are general guidelines—always err on the side of caution. Never exceed your comfort level.
Understanding Dosage Ranges
All dosage figures below refer to dried Psilocybe cubensis — the standard cultivated species and the reference point for virtually all published harm-reduction guidelines. A microdose falls between 0.05 and 0.3 g. At this range, effects are sub-perceptual: a well-calibrated microdose should not produce visual changes, impaired coordination, or obvious intoxication. Users following structured protocols such as the Fadiman protocol (one day on, two days off, repeating) or the Stamets stack (four days on, three days off, combined with lion's mane and niacin) typically report subtle mood lift, increased focus, and mild emotional openness. If any of those perceptual changes do appear, the dose is too high and should be reduced on the next scheduled day.
A low dose (0.5-1.5 g) produces noticeable but mild effects. Colors may appear slightly richer, mood brightens, and thinking takes on a looser, more associative quality. Most people remain substantially functional at this range, and some find social settings manageable, though operating vehicles or heavy machinery is never appropriate. This is the recommended entry point for anyone who has not previously used psilocybin.
The moderate dose range (1.5-3.5 g) constitutes the classic psychedelic experience. Geometric patterns and closed-eye visuals are common. Emotional content deepens, time perception distorts significantly, and introspective material can surface with intensity. Normal tasks are not possible at this level. Planning is essential: arrange several uninterrupted hours in a safe, comfortable environment with a trusted sober person available. The majority of published clinical research on psilocybin for depression, anxiety, and addiction used doses within this range (typically 20-30 mg of pure psilocybin, roughly equivalent to 2-3.5 g of cubensis).
A high dose (3.5-5 g) is a qualitatively different experience. Strong visual hallucinations appear in open and closed eyes. The boundary between self and environment begins to soften, sometimes referred to as ego softening or incipient ego dissolution. Profound emotional or mystical content is common and can be disorienting. This range is not appropriate for first-time users. A person choosing this range should have prior experience with moderate doses, a well-prepared set and setting, and a sober, experienced guide present throughout.
The heroic dose (5 g and above), a term associated with ethnobotanist Terence McKenna, involves complete ego dissolution in most individuals. Contact with ordinary reality becomes tenuous. This range is very rarely used in clinical or therapeutic settings, and its use outside of highly prepared, guided contexts carries meaningful psychological risk. It is suitable only for highly experienced users who have worked deliberately through lower ranges over multiple sessions, have engaged in serious psychological preparation, and have a trusted sober guide present for the entire duration.
Species Potency Differences
Psilocybe cubensis averages approximately 0.5-0.9% psilocybin by dry weight, which is why it serves as the dosage reference. Not all species share this profile, and using the wrong dose assumption with a more potent species is one of the most common causes of unexpectedly overwhelming experiences.
Panaeolus cyanescens (also called wavy caps or blue meanies) contains approximately 2-3 times the active alkaloid content of cubensis by weight. Taking the same gram-for-gram amount of this species as one would with cubensis can produce dramatically more intense effects than anticipated. Psilocybe cyanescens, common in Pacific Northwest foraging and wood-chip beds, typically runs 1.5-2 times cubensis potency. Psilocybe semilanceata (liberty caps), found widely across European meadows, can equal or exceed cyanescens potency and is notably variable between specimens from different regions and seasons. Psilocybe azurescens, among the most potent psilocybin-containing species identified to date, can reach 3-4 times cubensis potency.
The practical harm-reduction principle is straightforward: when working with any species other than well-characterized cubensis from a known source, begin at 50% of your usual dose. Then wait a full two hours before making any assessment of the effects. Potency differences between species have caught even experienced users off guard.
The Onset Delay: Why Redosing Is Dangerous
Psilocybin typically requires 20-60 minutes to produce noticeable effects after ingestion, but onset can extend to 90 minutes or longer, particularly when taken after a substantial meal. Gastric absorption rate varies between individuals and occasions. This delay is the source of one of the most common and avoidable dosing errors.
The scenario unfolds predictably: a person takes their intended dose, feels nothing at 45 minutes, concludes the mushrooms are weak or the dose was insufficient, and takes a second dose. Within the following 20-30 minutes, both doses are absorbed nearly simultaneously, producing an experience that is often double the intended intensity and potentially overwhelming. This is not theoretical — it is among the most frequently reported causes of acute distress calls to harm-reduction services such as the Fireside Project.
Redosing during an active experience also does not function the way users expect. Rapid tolerance develops within hours of an initial dose through 5-HT2A receptor downregulation. Additional psilocybin taken during an experience adds relatively little to the perceptual intensity but does add psychological content to an already fully engaged state. If an experience feels too intense, additional material will not provide relief — it will complicate an already demanding situation. The only appropriate responses to an overwhelming experience are grounding techniques, reassurance from a trusted person, and allowing time to pass.
The practical rule: choose a dose, take it in full, and commit to it. Do not redose within the first three hours under any circumstances. Any consideration of supplemental dosing after three hours should be made from a grounded, calm state, not from impatience during an active onset.
Measuring Accurately
Psilocybin mushrooms must be weighed on a calibrated digital scale. For microdoses, the scale must be accurate to 0.01 g (sometimes called a jewellery scale or precision scale). For full-dose ranges, a scale accurate to 0.1 g is the minimum acceptable standard. Kitchen scales and spoon measurements are not adequate — a single mushroom cap or stem segment can weigh anywhere from 0.1 g to over 1.5 g.
Potency is not uniformly distributed within a single mushroom or even within a single batch. Studies of Psilocybe cubensis potency distribution (including work by Stamets and Gartz on alkaloid content in cultured specimens) have documented 2-3 times variation between individual mushrooms from the same flush. Caps and stems also differ in alkaloid concentration. This means that two mushrooms of identical weight can produce meaningfully different experiences.
The most reliable method for reducing this variability is to grind an entire dried batch to a fine, homogeneous powder and mix it thoroughly before portioning doses. This averages out the within-batch variation and makes each measured portion representative of the batch as a whole. It also makes capsule filling straightforward and allows microdoses to be prepared in advance with reasonable consistency.
Tolerance and Spacing
Psilocybin produces rapid and near-complete pharmacological tolerance through serotonin receptor desensitization. In practical terms, a second full dose taken 24 hours after the first will produce substantially diminished effects. At 48 hours, tolerance remains significant. Meaningful tolerance reset requires approximately two weeks, and a four-week interval between moderate or high doses is the standard harm-reduction recommendation for people who use psilocybin repeatedly over time.
Cross-tolerance exists between psilocybin, LSD, and other serotonergic classical psychedelics. A person who used LSD recently may find that psilocybin effects are blunted in the days following, and vice versa. Planning the spacing of any serotonergic psychedelic use needs to account for this cross-tolerance.
For microdosing protocols, the off-days incorporated into both the Fadiman protocol (two days off after each dose day) and the Stamets stack (three days off per week) exist specifically to prevent tolerance accumulation. Daily microdosing negates the effects over time and is not recommended by practitioners in this area.
Contraindications That Affect Dosing
Certain medications and health conditions interact with psilocybin in ways that directly affect dose safety and should be understood before any use.
SSRIs and SNRIs (selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors) can significantly blunt psilocybin effects through chronic downregulation of serotonin receptors. Users taking these medications often find that standard doses produce little or no effect. The harm-reduction concern is that the instinct to compensate by increasing the dose is not straightforwardly safe — the interaction between SSRIs and psilocybin is pharmacologically complex and not fully characterized, and abrupt SSRI discontinuation to restore psilocybin sensitivity carries its own risks. This decision requires medical supervision.
Lithium represents an absolute contraindication. Case reports have documented seizures following the combination of lithium and psilocybin. This combination should not occur under any circumstances.
MAOIs (monoamine oxidase inhibitors), including certain antidepressants and the harmala alkaloids present in ayahuasca brews, inhibit the enzyme that metabolizes psilocin and can potentiate psilocybin effects dramatically. If combining these substances is considered, dose reduction to 25-30% of a standard amount is standard practice — and even this requires the guidance of someone with direct experience and expertise in these interactions.
Personal and family mental health history is also directly relevant to dosing decisions. Individuals with a personal or family history of psychosis, schizophrenia, or bipolar I disorder are at elevated risk of adverse psychological responses, and higher doses represent a substantially greater risk category for this population. Lower doses, if any, should only be approached with professional support.
The core principles of psilocybin harm reduction converge on the same practices regardless of context: weigh every dose on a calibrated scale, begin at the lower end of your intended range, allow the full onset window to pass before drawing any conclusions about effects, respect the two-week minimum between moderate experiences, and review all contraindications before each use. These are not overly conservative guidelines — they are the practical lessons distilled from clinical research, harm-reduction practice, and the direct experience of the communities that have worked with these substances over decades.